Sarah Doernberg, MD, MAS

Associate Professor

Infectious Diseases, Pulmonary, Critical Care, Allergy and Sleep Medicine

Sarah Doernberg is an Associate Professor in the Division of Infectious Diseases and the Medical Director of Adult Antimicrobial Stewardship at UCSF Medical Center. She has an active outpatient Infectious Diseases Clinic and sees inpatients on the Transplant Infectious Diseases service. Her clinical research focuses on healthcare-acquired infections and antimicrobial stewardship.

She received her BA from Harvard University in Biology with a focus in Neurobiology and received her MD from Yale University School of Medicine. She completed her Internal Medicine residency and Infectious Diseases fellowship at UCSF. She also received a Masters’ degree in advanced studies through the Training in Clinical Research Program at UCSF.

Fellowship, 2012 - Clinical Pharmacology and Therapeutics, University of California, San Francisco
M.A.S. in Clinical Research, 2012 - Graduate Division (Advance Training in Clinical Research), University of California, San Francisco
Fellowship, 2012 - Infectious Diseases, University of California, San Francisco
Residency, 2009 - Internal Medicine, University of California, San Francisco
M.D., 2006 - School of Medicine, Yale University
  1. Genomic Profiling of Evolving Daptomycin Resistance in a Patient with Recurrent Staphylococcus argenteus Sepsis.
  2. Machine learning for the prediction of antimicrobial stewardship intervention in hospitalized patients receiving broad-spectrum agents.
  3. Machine learning for the prediction of antimicrobial stewardship intervention in hospitalized patients receiving broad-spectrum agents.
  4. Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.
  5. Patients' Experiences with Staphylococcus aureus and Gram-Negative Bacterial Bloodstream Infections: A Qualitative Descriptive Study and Concept Elicitation Phase to Inform Measurement of Patient-Reported Quality of Life.
  6. Randomized trial evaluating clinical impact of RAPid IDentification and Susceptibility testing for Gram Negative bacteremia (RAPIDS-GN).
  7. Analytical evaluation of the Abbott RealTime CT/NG Assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal swabs.
  8. Will biomarkers be the answer for antibiotic stewardship?
  9. Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol.
  10. 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis.
  11. 2543. Implementation of a Fellow-Driven ?-Lactam Allergy De-Labeling Initiative on an Inpatient ID Consult Service.
  12. 2685. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies.
  13. 640. Randomized Clinical Trial Evaluating Clinical Impact of RAPid IDentification and Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN).
  14. 839. Effect of Clostridioides difficile (C. difficile) Toxin Test Reporting on Clinical Treatment and Outcomes of Toxin-Negative PCR-Positive Patients at Five California Hospitals.
  15. Sentinel Case of Candida auris in the Western United States Following Prolonged Occult Colonization in a Returned Traveler from India.
  16. Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).
  17. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.
  18. Things We Do For No Reason: Contact Precautions for MRSA and VRE.
  19. Perioperative Use and Safety of Cephalosporin Antibiotics in Patients with Documented Penicillin Allergy.
  20. 1818. Characteristics of a Cohort of Patients on Broad-Spectrum Antibiotics Targeted for Prospective Audit and Feedback.
  21. 415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis.
  22. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.
  23. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What is Happening in the Real-world Setting?
  24. Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing.
  25. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.
  26. Antimicrobial Stewardship Approaches in the Intensive Care Unit.
  27. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
  28. Disseminated Acanthamoeba infection in a heart transplant recipient treated successfully with a miltefosine-containing regimen: Case report and review of the literature.
  29. Analysis of CAMERA-1 S. aureus Bacteremia Trial Results Using the DOOR.
  30. Assessing the Impact of a Pharmacist-Managed Vancomycin Protocol on the Duration of Empiric Therapy.
  31. Assessing the Impact of an Automatic Antimicrobial Stewardship Review of Positive Blood Cultures in Patients with Gram-Negative or Gram-Positive Bloodstream Infections.
  32. BAC DOOR: A Clinician Ranking Exercise for Better Staphylococcus aureus Bacteremia Trial Design.
  33. Clinical Characteristics and Outcomes Among Individuals With Spinal Implant Infections: A Descriptive Study.
  34. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
  35. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
  36. Implementation of an antimicrobial stewardship program targeting residents with urinary tract infections in three community long-term care facilities: a quasi-experimental study using time-series analysis.
  37. 724Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with Staphylococcus aureus Bacteremia in a Safety-Net Hospital.
  38. 727Evaluating the Impact of Socioeconomic Status on Clinical Presentation in Patients with Staphylococcus aureus Bacteremia.
  39. Does doxycycline protect against development of Clostridium difficile infection?
  40. Risk factors for acquisition of extended-spectrum ß-lactamase-producing Escherichia coli in an urban county hospital.
  41. Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae.